Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar;59(3):434–441. doi: 10.2967/jnumed.117.202945

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

PMC Copyright notice

FIGURE 3. — A 67-y-old man with BCR (PSA level, 10.7 ng/mL; doubling time, 9.3 mo) of initially high-risk prostate cancer (Gleason 9; pT3a) 8 y after primary radical prostatectomy and adjuvant prostate bed irradiation. Intended prescan treatment was androgen deprivation therapy. ⁶⁸Ga-PSMA-11 PET/CT showed intense ⁶⁸Ga-PSMA-11 uptake (SUV_max, 7) in multiple lung nodules (yellow arrows) and thoracic lymph nodes (red arrows). Intended postscan treatment (Q2) was chemotherapy plus androgen deprivation therapy. CT-guided biopsy of upper left lung nodule confirmed metastatic prostatic adenocarcinoma. Patient elected to forgo chemotherapy because of potential side effects, and thus, intended postscan management (Q2) was not implemented. Actual management was androgen deprivation therapy alone, and thus, there was no change from prescan intended management as recorded on Q1. (A) ⁶⁸Ga-PSMA-11 PET maximum-intensity projection. (B) Axial CT, lung window. (C) Axial ⁶⁸Ga-PSMA-11 PET/CT, lung window. (D) Axial CT, mediastinal window. (E) Axial ⁶⁸Ga-PSMA-11 PET/CT, mediastinal window.